Lightstone Ventures
Lightstone Ventures is a venture capital firm established in 2012 and headquartered in Menlo Park, California, with additional offices in Boston, Dublin, and Singapore. The firm specializes in investing in early-stage and late-stage companies within the healthcare and life sciences sectors, focusing on personalized medicines, targeted therapeutics, medical devices, and novel biopharmaceuticals. By targeting innovative startups primarily in Europe and Australia, Lightstone Ventures aims to capitalize on advancements in life sciences and the unique opportunities within the industry. The firm is recognized as a Registered Investment Adviser, emphasizing its commitment to strategic investments in breakthrough technologies that can transform healthcare.
Fire1
Venture Round in 2025
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Fire1
Venture Round in 2023
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Carrick Therapeutics
Series C in 2022
Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Carrick Therapeutics
Series A in 2016
Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.